Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
he will still deny the UCLA DC vaccine = NWBO's DCVAXL
The only cemented that is good enough for a (license) deal, for a large pharma is UK approval.
Median follow-up of patients treated on this clinical trial was 2.2 years after surgery, although the long-term survivors have now been followed for over 10 years. Median progression-free survival (PFS) was 8.1 months; and median overall survival (OS) was 26.6 months.
median overall survival in present SOC for GBM currently is 9.2 months, that's an almost x3 improvement and counting
I think they already answered the questions asked in the RFI
You may very well be right about the buyout price. As I posted here yesterday Merck made (IMO) an opening bid for NWBO at $15 billion a few weeks ago
https://www.biopharmadive.com/news/merck-dealmaking-15-billion-keytruda-cliff-davis/706309/
100% agree. And yes I agree with you that at these depressed prices, LP will not sell NWBO. However, things can move very fast.. A large pharma making an upfront payment of $300 million for the right to sell DCVAXL in the UK on approval, SP to $4-$5 after approval, uplist SP to $ 7-$ 8 on Nasdaq. Rumors of buy out SP to $ 10- $12
Bam NWBO bought in .... December this year or Q1 next year.
The point I was making is of course that with a staff of 14 NWBO will not stay independent.
Also with NWBO's CTO residing 5000 miles to the East of NWBO HQ, no scientist at NWBO HQ (and no Dr Liau is not working full-time for NWBO). no medical trial experts working for NWBO....
NWBO is NOT capable of organizing even a Red Cross exercise let alone a new joint medical trial, let alone multiple medical trials.
They will be bought within 6-9 months after UK approval.
exactly. The Delaware court is not favorable of management screwing over small retail shareholders
yes you are right that the court has not made a final judgment but if you read what the Delaware court opinion is then you can easily see where this is going.
Trust NWBO when they say in their 10K/Q that DCVAXL needs to be A) marketed B) sold C) (most importantly) sales supported.
You cant expect MDs, caregivers, surgeons, patients etc to just start guessing what DCVAXL is, how it should be administered, what is needed, what is to be expected etc etc etc
Ooh and if you are talking globally now. Who within NWBO will be discussing reimbursement policy with the hundreds of insurance companies and governments in (after UK NICE) Canada, 27 EU member states, the US, Australia, Japan, South Korea, some countries in South America, Switzerland, Norway etc etc etc?
Les? Linda? I think not
NWBO will be bought
As I have said here a few times I think NWBO will be bought for a price between $15 billion on the low end
https://www.biopharmadive.com/news/merck-dealmaking-15-billion-keytruda-cliff-davis/706309/
exactly
NWBO will not be selling DCVAXL because they are not capable of selling, marketing, and most importantly sales supporting DCVAXL. Therefore there will be no revenue generated by NWBO as an independent biotech in the UK in 2025. Anyone who thinks a cancer drug therapy such as DCVAXL can just sells itself without any support from a well-prepared cancer drug sales support department does not understand the workings of biotech. As of today, NWBO only has Les's wife Sue Goldman to sell support the compassionate use of DCVAXL. The assertion that present NWBO/Sue will be able to explain, instruct market, and sell DCVAXL to 362 consultant neurosurgeons and or 1,078 clinical oncologists and 3,200 patients and their caregivers in the UK is absurd. As long as NWBO is not hiring a single qualified sales support staff they are not planning to sell DCVAXL. As long as NWBO is not hiring anyone to sale support DCVAXL, they are planning to be bought after UK approval.
From NWBO's last 10K
No its noy It's NOT 210 business days, its 210 regular days.
the tote bag is still one of my all time favourites lol
I agree as long as the market will see a potent non dilutive cash influx into NWBO. Plus uplisting is very important to NWBO since that will allow institutional investors to start buying NWBO shares (as they now are often not allowed to buy OTC stocks)
Since Jan 1 2024 the MHRA did a great overhaul and shortened the approval process drastically. So the 150 days timeline ex RFI timeout of max 60 days is very doable. But you knew that already and keep rehashing your bogus approval timelines from 2023
the selling volume is a combination of retailers desperate to pay their bills, traders taking profit, market maker manipulation and short sellers selling to establish short positions. It doesn't matter the problem is that NWBO stock does not have institutional buyers because of OTC and OTC is only offered at 1/3 of the trading platforms. Therefore I don't see the SP increase significantly without uplist and nondilutive financing even after UK approval.
so much for the great SP run-up. It was great while it 2 days lasted. We need to uplist and we need nondilutive financing news
I predict that if there is no other news than UK approval we will be lucky to see the stock tick 1.4 then fall back sub $1 again after UK approval